Karau, Melissa J.
Mandrekar, Jay
Lehoux, Dario
Schuch, Raymond
Cassino, Cara
Patel, Robin
Funding for this research was provided by:
ContraFect Corporation
Article History
Received: 23 February 2023
Accepted: 22 August 2023
First Online: 11 September 2023
Declarations
:
: Mayo Clinic Institutional Review Board approved the use (IRB #1770-00) of clinical isolate MRSA IDRL-6169 for use in this study.
: Not applicable.
: RS, CC and DL were employed at Contrafect Corporation at the time the work was being completed. DL assisted in designing the study. RS, CC and DL reviewed the data and approved the final manuscript. MK and JM have no interests to declare. RP reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire; is a consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and HealthTrackRx with monies paid to Mayo Clinic. RP has research supported by Adaptive Phage Therapeutics, is a consultant to Netflix, Abbott Laboratories, and CARB-X and has a patent on <i>Bordetella pertussis/parapertussis</i> PCR issued, on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and on an anti-biofilm substance. RP receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course.